Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer

 Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer

Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer

Shots:

  • The P-III IMpassion031 study involves assessing of Tecentriq + CT (Abraxane, nab-paclitaxel; followed by doxorubicin and cyclophosphamide) vs PBO + CT in 333 people in a ratio (1:1) with previously untreated, early TNBC, regardless of PD-L1 expression
  • Results: met its 1EPs by demonstrating a clinically meaningful improvement in pathological complete response. Patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery, regardless of PD-L1 expression
  • Tecentriq + nab-paclitaxel is currently approved in 70+ countries worldwide, including the US and across EU, for the treatment of adults with unresectable LA/metastatic TNBC in people whose tumors express PD-L1

Click here to read full press release/ article | Ref: Roche | Image: Roche

Related News: Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post